Targeting Wnt5A signaling to improve treatment for advanced prostate cancer
Therapeutic targeting Wnt5A signaling for advanced prostate cancer
This study is looking at how a specific signaling process called Wnt5A affects advanced prostate cancer that doesn't respond to common treatments, with the goal of finding new ways to make these treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10986078 on NIH RePORTER |
What this research studies
This research investigates the role of Wnt5A signaling in advanced prostate cancer, particularly in cases resistant to common treatments like enzalutamide and abiraterone. The study aims to understand how Wnt5A contributes to drug resistance and to develop new strategies to inhibit this signaling pathway. By exploring two novel approaches to target Wnt5A, the research seeks to enhance the effectiveness of existing therapies and potentially resensitize cancer cells to treatment. Patients may benefit from insights that could lead to improved therapeutic options for advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who have developed resistance to enzalutamide or abiraterone.
Not a fit: Patients with early-stage prostate cancer or those who have not yet received treatment with enzalutamide or abiraterone may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment strategies that enhance the effectiveness of current therapies for advanced prostate cancer.
How similar studies have performed: Previous studies have shown promising results in targeting Wnt signaling pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Gao, Allen C. — University of California at Davis
- Study coordinator: Gao, Allen C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.